This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Translational Prostate Cancer
        • Women in Science
          Andrea Miyahira, Ph.D
        • Health Policy
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
    • Trials in Progress
      • DORA - PCCTC
      • IRONMAN - PCCTC
      • PROMISE - PCCTC
      • SPLASH Trial
      • Oral EPI-7386
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SUO 2022
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Conference Highlights

ASCO GU 2022

ASCO GU 2022 Prostate Cancer

  • ASCO GU 2022: A Path Forward: Addressing Disparities in Genitourinary Cancers
  • ASCO GU 2022: Treatment Outcomes for mCRPC Following Progression on Upfront ADT with Androgen Receptor Pathway Inhibitors for mCSPC
  • ASCO GU 2022: The TRAP Trial: Targeting Resistant Prostate Cancer, with or without DNA Repair Defects, Using the Combination of Ceralasertib and Olaparib
  • ASCO GU 2022: Real-World Health-Related Quality of Life and Caregiver Needs in Patients with mHSPC and mCRPC
  • ASCO GU 2022: Real-World Analyses of Major Adverse Cardiovascular Event Risk by Drug Class After Initiation of ADT
View all (172 articles)

ASCO GU 2022 Penile, Urethral, Testicular, and Adrenal Cancers

  • ASCO GU 2022: Endocrine Tumors of the Genitourinary Tract
  • ASCO GU 2022: First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients: The ADIUVO Study
  • ASCO GU 2022: Clinical Results of PERICLES: A Phase II Trial Investigating Atezolizumab +/- Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis
  • ASCO GU 2022: The PRIMETEST Trial: Prospective Phase II Trial of Primary Retroperitoneal Lymph Node Dissection in Stage II A/B Patients With Seminoma
  • ASCO GU 2022: Optimization of Serum miR-371a-3p for the Detection of Chemotherapy-Naïve Minimal Residual Germ Cell Tumor
View all (8 articles)

ASCO GU 2022 Press Releases

  • Positive Results from Phase III Investigational Trial Shows NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy (ADT) and Docetaxel Significantly Increases Overall Survival (OS) in Patients with mHSPC
  • Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
  • Biomarker for Bladder Cancer Survival: Results From the SWOG 1314 Clinical Trial
  • Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer
  • New Genetic Risk Score Stratifies Lifetime Risk of Dying of Prostate Cancer in Diverse Populations
View all (11 articles)

ASCO GU 2022 Bladder Cancer

  • ASCO GU 2022: Bladder-Sparing Trimodality Therapy: Toxicity and Functional Outcomes in the Era of Novel Therapeutics
  • ASCO GU 2022: First-Line Pembrolizumab with or Without Lenvatinib in Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Study.
  • ASCO GU 2022: ABLE: Phase 2, Single-Arm, Two-Stage Study of Nab-Paclitaxel with Anti-PD1/PDL1 in Advanced Urothelial Cancer
  • ASCO GU 2022: Biomarker Analysis and Updated Clinical Follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy
  • ASCO GU 2022: First-Line Pembrolizumab in Advanced Urothelial Carcinoma: Clinical Parameters Associated with Efficacy in the Phase 2 KEYNOTE-052 and Phase 3 KEYNOTE-361 Trials
View all (78 articles)

ASCO GU 2022 Kidney Cancer

  • ASCO GU 2022: Matching Sequencing Reports With Available Therapies in Renal Cell Carcinoma
  • ASCO GU 2022: Current Data on Predictive Biomarkers in Renal Cell Carcinoma
  • ASCO GU 2022: Germline Mutations of Interests in Renal Cell Carcinoma
  • ASCO GU 2022: Adjuvant and Consolidative Therapy in Oligometastatic Renal Cell Carcinoma
  • ASCO GU 2022: Updates on Clinical Trials in First-Line Metastatic Renal Cell Carcinoma Plus Novel Pathways and Endpoints
View all (43 articles)

ASCO GU 2022 Upper Tract Urothelial Carcinoma

  • ASCO GU 2022: New Evidence to Optimize Bladder Preservation
  • ASCO GU 2022: Endoscopic Management of Low-Grade Upper-Tract Urothelial Carcinoma
  • ASCO GU 2022: Defining Hereditary Upper Tract Urothelial Carcinoma: Implications for Genetic Testing and Clinical Management
  • ASCO GU 2022: Survival Outcomes Comparing Radical Nephroureterectomy Versus Endoscopic Treatment in Solitary Kidney Patients Diagnosed With Upper Tract Urothelial Carcinoma
View all (4 articles)
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free